Conduit Pharmaceuticals (CDT) said Friday that it has engaged NJS Foresight Bio-Advisor to identify, source, and support out-licensing deals for in its patent portfolio.

The hiring is meant to expand CDT's commercial reach and speed up potential licensing and royalty deals for its cocrystals and salts, which are meant to improve the solubility, bioavailability and alternative delivery modes of medicines, the company said.